Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs-Reference-Cited by-同舟云学术

Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Published:2014-08-10 Issue:9 Volume:21 Page:803-809
ISSN:1545-9993
Container-title:Nature Structural & Molecular Biology
language:en
Short-container-title:Nat Struct Mol Biol

Author:

Chamberlain Philip P,Lopez-Girona Antonia,Miller Karen,Carmel Gilles,Pagarigan Barbra,Chie-Leon Barbara,Rychak Emily,Corral Laura G,Ren Yan J,Wang Maria,Riley Mariko,Delker Silvia L,Ito Takumi,Ando Hideki,Mori Tomoyuki,Hirano Yoshinori,Handa Hiroshi,Hakoshima Toshio,Daniel Thomas O,Cathers Brian E

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Structural Biology

Link

http://www.nature.com/articles/nsmb.2874.pdf

Reference43 articles.

1. Petroski, M.D. The ubiquitin system, disease, and drug discovery. BMC Biochem. 9 (suppl. 1), S7 (2008).

2. Eve, H.E. et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br. J. Haematol. 159, 154–163 (2012).

3. Quach, H. et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24, 22–32 (2010).

4. Ramsay, A.G., Clear, A.J., Fatah, R. & Gribben, J.G. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120, 1412–1421 (2012).

5. Ramsay, A.G. et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 121, 2704–2714 (2013).

Cited by 388 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation;Journal of Hematology & Oncology;2024-09-02

2. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications;European Journal of Medicinal Chemistry;2024-09

3. Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases;Journal of Medicinal Chemistry;2024-08-16

4. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08

5. Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment;International Journal of Biological Macromolecules;2024-08